ConductScience.org, home

Paper830758

Host cell modification of lymphocytic choriomeningitis virus and Newcastle disease virus altering viral inactivation by human complement.

Welsh RM. J Immunol, 1977. Cited by 57 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Host cell modification of lymphocytic choriomeningitis virus and Newcastle disease virus altering viral inactivation by human complement. Papers, record 830758. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/830758

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Host cell modification of lymphocytic choriomeningitis virus and Newcastle disease virus altering viral inactivation by human complement.
PubMed
Journal
J Immunol
PubMed
Year
1977
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
57
iCite
Relative citation ratio, by iCite
1.35
iCite
Revised in PubMed
2019-12-10
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Welsh RMR M

Source PubMed

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Complement System ProteinsMajor topic
Lymphocytic choriomeningitis virusMajor topic
Newcastle disease virusMajor topic
Animals
Cell Line
L Cells
Virus Cultivation

Source PubMed

Cited by31

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 57 citations.

PMIDTitleJournalYearIn PapersSource
41,766,922The oncolytic vesicular stomatitis virus VSV-GP shows profound oncolytic activity in NUT-carcinoma cell lines.Mol Ther Oncol2026https://conductscience.org/library/papers/41766922PubMed
41,685,933Monoclonal IgM antibodies mediate potent complement neutralization by targeting cell-derived epitopes on enveloped viruses.mBio2026https://conductscience.org/library/papers/41685933PubMed
33,133,089In the Crosshairs: RNA Viruses OR Complement?Front Immunol2020https://conductscience.org/library/papers/33133089PubMed
32,214,620Antibody and complement-dependent viral neutralization.Springer Semin Immunopathol1979https://conductscience.org/library/papers/32214620PubMed
28,670,306Complement Evasion Strategies of Viruses: An Overview.Front Microbiol2017https://conductscience.org/library/papers/28670306PubMed
25,927,683Prevalence and characterization of murine leukemia virus contamination in human cell lines.PLoS One2015https://conductscience.org/library/papers/25927683PubMed
25,409,303An AGM model for changes in complement during pregnancy: neutralization of influenza virus by serum is diminished in late third trimester.PLoS One2014https://conductscience.org/library/papers/25409303PubMed
23,740,988Possible role of a cell surface carbohydrate in evolution of resistance to viral infections in old world primates.J Virol2013https://conductscience.org/library/papers/23740988PubMed
22,973,037Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion.J Virol2012https://conductscience.org/library/papers/22973037PubMed
22,761,385Virion-associated complement regulator CD55 is more potent than CD46 in mediating resistance of mumps virus and vesicular stomatitis virus to neutralization.J Virol2012https://conductscience.org/library/papers/22761385PubMed
21,450,814Interactions of human complement with virus particles containing the Nipah virus glycoproteins.J Virol2011https://conductscience.org/library/papers/21450814PubMed
19,457,998The paramyxoviruses simian virus 5 and mumps virus recruit host cell CD46 to evade complement-mediated neutralization.J Virol2009https://conductscience.org/library/papers/19457998PubMed
18,440,578Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus.Virology2008https://conductscience.org/library/papers/18440578PubMed
10,523,614Protective T cell-independent antiviral antibody responses are dependent on complement.J Exp Med1999https://conductscience.org/library/papers/10523614PubMed
10,467,364Human serum-resistant retroviral vector particles from galactosyl (alpha1-3) galactosyl containing nonprimate cell lines.Gene Ther1999https://conductscience.org/library/papers/10467364PubMed
9,573,228Evaluation of the Galalpha1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses.J Virol1998https://conductscience.org/library/papers/9573228PubMed
8,676,446Immune evasion properties of herpes simplex virus type 1 glycoprotein gC.J Virol1996https://conductscience.org/library/papers/8676446PubMed
7,966,590Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell.J Virol1994https://conductscience.org/library/papers/7966590PubMed
7,595,205A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody.J Exp Med1995https://conductscience.org/library/papers/7595205PubMed
7,045,625The complement system: its importance in the host response to viral infection.Microbiol Rev1982https://conductscience.org/library/papers/7045625PubMed

See all 31 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/830758

GET https://conductscience.org/api/papers/v1/830758/cited_by?page=2